ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.866,04
2,49%
Brent Oil
83,76
0,67%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Aventis New Ads (AVE)

  7. Aventis New Ads (AVE) Notícias

AVE

Aventis (AVE)

Aventis New Ads
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:AVE
DataHoraFonteTítuloCódigoCompanhia
15/10/200418:03PR Newswire (US)Rhone-Poulenc Overseas Limited Announces Redemption of All Outstanding Cumulative Guaranteed Preference Shares, Series ANYSE:AVEAventis New Ads
04/10/200416:44PR Newswire (US)Aventis Ships 30 Million Doses of Influenza Vaccine to Health-Care ProvidersNYSE:AVEAventis New Ads
22/09/200418:23PR Newswire (US)Advisory Panel Recommends FDA Licensure of Aventis' Menactra(TM) Vaccine for Protection Against Meningococcal DiseaseNYSE:AVEAventis New Ads
21/09/200410:30PR Newswire (US)Aventis Named to List of Top 100 Companies for Working MothersNYSE:AVE
16/09/200404:00PR Newswire (US)The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual IdentityNYSE:AVE
14/09/200410:30PR Newswire (US)Coley Pharmaceutical Group Receives Payment From Aventis for Clinical Milestone in Collaboration on Allergic Respiratory DiseaseNYSE:AVEAventis New Ads
19/08/200410:00PR Newswire (US)FDA Approves Taxotere(R) for the Treatment of Women with Early Stage Breast CancerNYSE:AVEAventis New Ads
11/08/200412:39PR Newswire (US)Aventis Submits Application for FDA Licensure of ADACEL(TM) Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in AdoleNYSE:AVEAventis New Ads
05/08/200421:02PR Newswire (US)Ventiv Health Announces Sales and Marketing Agreement with AventisNYSE:AVEAventis New Ads
03/08/200415:58PR Newswire (US)FDA Approves Sculptra(TM) (Injectable Poly-L-Lactic Acid)NYSE:AVEAventis New Ads
28/07/200416:31PR Newswire (US)Aventis Reports Second-Quarter and First-Half Results for 2004NYSE:AVEAventis New Ads
27/07/200412:29PR Newswire (US)Aventis to Move Forward With Reissuance Process for Contested Lovenox PatentNYSE:AVE
07/07/200410:00PR Newswire (US)New Data Confirm Lovenox(R) is an Effective Antithrombotic for Treatment of Acute Coronary SyndromesNYSE:AVE
23/06/200411:50PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis Expiration Date of OffersNYSE:AVE
14/06/200412:43PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis DividendNYSE:AVE
07/06/200414:00PR Newswire (US)Two Landmark Studies Show That Taxotere(R) Significantly Improves Survival in Men With Prostate CancerNYSE:AVEAventis New Ads
05/06/200411:00PR Newswire (US)Investigators Report Taxotere(R) Offers Significant Survival Benefits for Head and Neck Cancer PatientsNYSE:AVEAventis New Ads
28/05/200414:00PR Newswire (US)Genta and Aventis Announce Termination of Genasense(TM) Expanded Access Program in MelanomaNYSE:AVEAventis New Ads
27/05/200404:00PR Newswire (US)Aventis and U.S. NIH Enter Into Pandemic Influenza Vaccine AgreementNYSE:AVE
26/05/200412:05PR Newswire (US)Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004NYSE:AVE
26/05/200410:00PR Newswire (US)Two Landmark Studies of Taxotere(R) in Prostate Cancer Highlighted in American Society of Clinical Oncology Plenary SessionNYSE:AVEAventis New Ads
23/05/200414:15PR Newswire (US)Data Show Once-Daily Alvesco(R) (ciclesonide) Has No Effect on HPA-Axis Function in Asthma PatientsNYSE:AVE
23/05/200414:15PR Newswire (US)Surveillance Study Finds Newly-Approved Antibiotic KETEK(R) (telithromycin) Tablets 99% Effective In Vitro Against StreptococcusNYSE:AVE
19/05/200416:39PR Newswire (US)Aventis Receives FDA Approval for Taxotere(R) in Prostate CancerNYSE:AVEAventis New Ads
18/05/200410:01PR Newswire (US)Aventis Receives Priority Review Designation for the Registrational Application to Support the Use of Taxotere(R) in Women withNYSE:AVE
05/05/200412:12PR Newswire (US)Sanofi-Synthelabo's Offer for AventisNYSE:AVE
03/05/200416:52PR Newswire (US)FDA Advisory Committee Reviews Genasense(TM) for Use in Advanced MelanomaNYSE:AVEAventis New Ads
30/04/200416:55PR Newswire (US)Aventis Pasteur Statement on New Influenza Immunization Recommendations for Infants, Young Children and Their Close ContactsNYSE:AVE
29/04/200415:03PR Newswire (US)Aventis Reports First-Quarter Results for 2004NYSE:AVE
27/04/200411:52PR Newswire (US)Approval by The European Commission of the Planned Acquisition of Aventis By Sanofi-SynthelaboNYSE:AVE
 Apresentando as notícias mais relevantes sobre:NYSE:AVE

Seu Histórico Recente

LSE
NSN
EU
ESGFP
Euronext France ESG Lead...
AMEX
BGSF
BG Staffing
USOTC
PKCOF
Park 24 (PK)
BIT
UI346A
Unicredit Bank
TSX
XMF.A
M Split
USOTC
SBNCN
Southern Bancshares N C (PK)
LATK
BOBBTC
BOB Token
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados